SCHEMBL22645007

SCHEMBL22645007

CNc1c(C(C)=O)sc2nc(C)cnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.47
ALDH1A1 P00352 8/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 3/20 0.47
HTT P42858 1/20 0.47
GAA P10253 4/20 0.38
MAPT P10636 3/20 0.38
ATM Q13315 2/20 0.38
RAB9A P51151 3/20 0.38
POLB P06746 3/20 0.38
IKBKB O14920 1/20 0.38
CHUK O15111 1/20 0.38
PRKACA P17612 1/20 0.38
PRKACG P22612 1/20 0.38
PRKACB P22694 1/20 0.38
LIMK1 P53667 1/20 0.38
BTK Q06187 1/20 0.38
MITF O75030 1/20 0.38
TP53 P04637 1/20 0.38
PAX8 Q06710 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24248117 0.87 IKBKB (0.49) KDM4EALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL24248137 0.87 KDM4E (0.40) KDM4EALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL20732017 0.79 KDM4E (0.60) KDM4EALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL22645006 0.75 LIMK1 (0.52) KDM4EALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL24248138 0.71 SMN1; SMN2 (0.41) KDM4EALDH1A1SMN1; SMN2HPGDGAA
SCHEMBL20731112 0.70 IKBKB (0.60) KDM4EALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL19211014 0.70 USP28 (0.47) KDM4EALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL21457814 0.70 KDM4E (0.63) KDM4EALDH1A1SMN1; SMN2HPGDGAA
SCHEMBL24248139 0.68 ALDH1A1 (0.39) KDM4EALDH1A1SMN1; SMN2HPGDHTT
SCHEMBL24248129 0.66 USP28 (0.44) KDM4EALDH1A1SMN1; SMN2HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213118-A1 UBIQUITIN-SPECIFIC PROTEASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOFF CHASER THERAPEUTICS, INC. (CN) 2022-07-07 US disclosed
EP-3954694-A1 UBIQUITIN-SPECIFIC PROTEASE INHIBITORS, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Chaser Therapeutics, Inc. (CN) 2022-02-16 EP disclosed
WO-2020224652-A1 UBIQUITIN-SPECIFIC PROTEASE INHIBITORS, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 北京普济远成生物科技有限公司 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213118-A1 UBIQUITIN-SPECIFIC PROTEASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOFF USP28, USP25, USP24 KDM4E 2500/4885ALDH1A1 1156/4885SMN1; SMN2 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.